Familial Dysbetalipoproteinemia in Three Patients with apoE 2*(Arg136→Cys) Gene Variant

Physiological Research

Volumn 52, Issue 5, 2003, Pages 647-650

  Vrablík, Michal ^a,b   Horinek A ^a   Ceska R ^a   Stulc T ^a   Kvasnicka T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

Apolipoprotein E; Familial dysbetalipoproteinemia; Rare variants

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; ARGININE; CHOLESTEROL; CYSTEINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; LIPOPROTEIN A; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CASE REPORT; DOMINANT INHERITANCE; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HETEROZYGOTE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; MALE; PHENOTYPE; PROTEIN ANALYSIS; XANTHOMATOSIS;

AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; DNA; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, AGAR GEL; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 0242385615     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. DE KNIJFF P, VAN DEN MAAGDENBERG AMJM, FRANTS RR, HAVEKES LM: Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat 4: 178-194, 1994.
2. FEUSSNER G, ALBANESE M, MANN WA, VALENCIA A, SCHUSTER H: Apolipoprotein E2 (Arg136→Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia. Eur J Clin Invest 26: 13-23, 1996.
3. FEUSSNER G, FEUSSNER V, HOFFMAN MM, LOHRMANN J, WIELAND H, MARZ W: Molecular basis of type III hyperlipoproteinemia in Germany. Hum Mutat 11: 417-423, 1998.
4. HIXSON JE, VERNIER DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1: 545-548, 1990.
5. HOŘEJŠÍ B, ČEŠKA R: Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein (a) as candidate genes of premature development of atherosclerosis. Physiol Res 49 (Suppl 1): S63-S69, 2000.
6. HUBÁČEK JA, PIŤHA J, STÁVEK P, SCHMITZ G, POLEDNE R: Variable expression of hypercholesterolemia in apolipoprotein E 2*(Arg136→Cys) heterozygotes. Physiol Res 49: 307-314, 2000.
7. HUBÁČEK JA, PIŤHA J, ŠKODOVÁ Z, POLEDNE R: Rare variant of apolipoprotein E 2*(Arg136→Cys) in a subject with normal lipid values. Physiol Res 51: 107-108, 2002.
8. MÄRZ W, HOFFMAN MM, SCHARNAGL H, FISHER E, CHEN M, NAUCK M, FEUSSNER G, WIELAND H: Apolipoprotein E2 (Arg136→Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia. J Lipid Res 39: 658-669, 1998.
9. RALL SC Jr., MAHLEY RW: The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med 231: 653-659, 1992.
10. UTERMANN G. Apolipoprotein E polymorphism in health and disease. Am Heart J 113: 443-440, 1987.
11. WALDEN CC, HUFF MW, LEITER LA, CONNELY PW, HEGELE RA: Detection of a new apolipoprotein E mutation in type III hyperlipidaemia using deoxyribonucleic acid restriction isotyping. J Clin Endocrinol Metab 78: 699-704, 1994.